Provided by Tiger Fintech (Singapore) Pte. Ltd.

NRX Pharmaceuticals Inc.

3.12
-0.0500-1.58%
Post-market: 3.230.1100+3.53%19:51 EDT
Volume:315.01K
Turnover:992.78K
Market Cap:74.16M
PE:-1.33
High:3.24
Open:3.24
Low:3.10
Close:3.17
52wk High:6.01
52wk Low:1.10
Shares:23.77M
Float Shares:16.42M
Volume Ratio:0.59
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3483
EPS(LYR):-2.3605
ROE:-682.61%
ROA:-174.88%
PB:-2.08
PE(LYR):-1.32

Loading ...

BRIEF-NRx Pharmaceuticals Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

Reuters
·
Aug 27

NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announces Expanded Access Policy for NRX-100 (Preservative-Free Ketamine)

THOMSON REUTERS
·
Aug 27

NRX Pharmaceuticals Inc. Files Initial Beneficial Ownership Statement for B Group, Inc

Reuters
·
Aug 21

NRX Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 20

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Aug 19

BRIEF-NRX Pharmaceuticals Reports Second Quarter 2025 Financial Results

Reuters
·
Aug 18

NRX Pharmaceuticals Q2 EPS $(0.98) Misses $(0.20) Estimate

Benzinga
·
Aug 18

NRX Pharmaceuticals Inc: Applying for a Pdufa Fee Waiver for NRX-101 From FDA

THOMSON REUTERS
·
Aug 18

NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 18

NRX Pharmaceuticals Inc: Believes That Its Current Cash Position Will Support Operations Into 2026

THOMSON REUTERS
·
Aug 18

Press Release: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 18

NRX Pharmaceuticals Inc Files for Offering of 3.9 Mln Shares of Common Stock to Some Accredited Investors at $1.65 per Share- SEC Filing

THOMSON REUTERS
·
Aug 18

NRX Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
Aug 16

NRX Pharmaceuticals Secures Fast Track Designation from FDA for NRX-100, Aiming to Combat Suicidal Depression

Reuters
·
Aug 15

NRX Pharmaceuticals Inc. Announces Second Quarter 2025 Financial Results Release

Reuters
·
Aug 14

NRX Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
Aug 13

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

GlobeNewswire
·
Aug 12

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Aug 11

NRX Pharmaceuticals Granted FDA Fast Track Designation for NRX-100 to Address Suicidal Ideation in Depression Patients

Reuters
·
Aug 11

NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients With Depression, Including Bipolar Depression

THOMSON REUTERS
·
Aug 11